- Company
- Janssen revs up 2 new global trials on lazertinib
- by An, Kyung-Jin Jun 4, 2020 06:14am
- Janssen’s novel anticancer treatment lazertinib licensed out from Yuhan is initiating a new global clinical trial. Prior to a global phase 2 trial, the multinational company is accelerating the investigational drug’s commercialization process with other phase 1 trials. According to a clinical trial registration website ‘clinicaltrials
- Company
- 3 out of 10 executives, worries about poor performance
- by Chon, Seung-Hyun Jun 3, 2020 06:40am
- The executives working at the pharmaceutical company pointed out the poor performance after COVID-19 outbreak. Most people pointed out that the company should reduce its performance targets to minimize damage to COVID-19. On the 21st anniversary of its founding, Dailypharm conducted a survey of “Post COVID-19 Crisis Response Strategy”
- Company
- Cancer Committee to review 3 signature drugs by BMS-Celgene
- by Eo, Yun-Ho Jun 3, 2020 06:25am
- On June 3, the Cancer Deliberation Committee is to review granting coverage on key products by the combined company of Bristol Myers Squibb (BMS) and Celgene. Celgene’s multiple myeloma pipelines&8212;Revlimid (lenalidomide) and Pomalyst (Pomalidomide)&8212;and BMS’ immunotherapy Opdivo (nivolumab) plus Yervoy (ipilimumab) combinatio
- Company
- AbbVie’s psoriasis drug Skyrizi NHI listed from June 1
- by Eo, Yun-Ho Jun 3, 2020 06:25am
- Another interleukin inhibitor has been listed for National Health Insurance (NHI) reimbursement. AbbVie Korea announced the Korean health authority is providing healthcare reimbursement on severe psoriasis treating interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab) from June 1. The coverage would be granted to patients with chro
- Company
- 'Champix' sales rebounded 13% in one year
- by Kim, Jin-Gu Jun 3, 2020 06:25am
- Pfizer's anti-smoking supplement Champix (Varenicline) has been successful in rebounding sales. It increased by 13% compared to the first quarter of last year. It is an analysis that it benefited from winning the patent dispute with generics. According to the drug analysis agency IQVIA on the 29th, the sales of Champix in the first quar
- Company
- New anticancer drugs by Bayer have been approved in Korea
- by Eo, Yun-Ho Jun 2, 2020 06:09am
- Two new drugs of Bayer's anticancer drugs will enter the domestic market. Androgen Receptor Inhibitor (ARi), Nubeqa (Darolutamide), treatment for nmCRPC and Orbital Selective Tropomyosin Receptor Kinase (TRK) inhibitor, Vitrakvi (Larotretinib) was recently approved by the MFDS. Nubeqa is an androgen receptor inhibitor with a unique chem
- Company
- Prescription drop amid COVID-19 finally emerges in April
- by Chon, Seung-Hyun Jun 2, 2020 06:09am
- The outpatient prescription volume in April has dropped by 10 percent against the same month last year. The outcome contrasts to this year’s first quarter prescription volume showing an increase against last year. Although the COVID-19 confirmed case curve in Korea seems to have gone down from April, the prescription volume shrunk even worse.
- Company
- Ilyang’s Supect were approved for phase III in Russia
- by Lee, Seok-Jun Jun 1, 2020 06:19am
- Ilyang announced on the 28th that its domestically developed new drug, Supect, will be conducting phase III clinical trials in Russia for the purpose of treating COVID-19. According to the company, Supect received phase III approval of 'COVID-19 treatment' from the Russian government under the supervision of R-Pharm, the No. 1 company in t
- Company
- KRPIA-MOHW talk negotiation, prioritized lisiting and PVA
- by Eo, Yun-Ho May 29, 2020 06:16am
- “Nothing was clarified, but we could somewhat feel out their approach.” For the first time since new Director Yang Yoon Seok was appointed, the Division of Pharmaceutical Benefits at Ministry of Health and Welfare (MOHW) met with a couple of dozen Korean Research-based Pharmaceutical Industry Association (KRPIA) officials and multination
- Company
- Alvogen Korea secures domestic rights for Evista
- by An, Kyung-Jin May 28, 2020 10:06am
- Alvogen Korea took over the domestic rights of 'Evista', an osteoporosis treatment for Takeda. Alvogen Korea announced on the 26th that it had obtained domestic permission for the osteoporosis treatment drug, Evista ( Raloxifene ) from Takeda Pharmaceuticals on the 25th. Evista is a second-generation estrogen receptor modulator (SERM)
